Tags

Type your tag names separated by a space and hit enter

A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis.
Int J Clin Pract. 2000 Jun; 54(5):293-9.IJ

Abstract

To compare the efficacy and safety of five-day cefdinir treatment with seven-day loracarbef treatment in patients with acute exacerbations of chronic bronchitis, 586 patients were enrolled in a multicentre, randomised, double-blind trial. Patients received either five days of treatment with cefdinir (n = 291) at 300 mg twice daily or seven days of treatment with loracarbef (n = 295) at 400 mg twice daily. Microbiological assessments were done on sputum specimens obtained at admission and at the two post-therapy visits, if available. The clinical cure rates were 86% (138/160) and 85% (141/166) for the evaluable patients treated with cefdinir and loracarbef, respectively. Respiratory tract pathogens were isolated from 457 (78%) of 586 admission sputum specimens, with the predominant pathogens being Haemophilus parainfluenzae, H. influenzae, Moraxella catarrhalis and Staphylococcus aureus. The microbiological eradication rates at the test-of-cure visit were 88% (193/219 pathogens) and 90% (227/251 pathogens) for the evaluable patients treated with cefdinir and loracarbef, respectively. Adverse event rates while on treatment were 30% and 21% for cefdinir- and loracarbef-treated patients, respectively. These results indicate that a five-day regimen of cefdinir is effective and safe for the treatment of patients with acute exacerbations of chronic bronchitis.

Authors+Show Affiliations

Dean Medical Center, Oregon, Wisconsin, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10954955

Citation

Paster, R Z., et al. "A Comparison of a Five-day Regimen of Cefdinir With a Seven-day Regimen of Loracarbef for the Treatment of Acute Exacerbations of Chronic Bronchitis." International Journal of Clinical Practice, vol. 54, no. 5, 2000, pp. 293-9.
Paster RZ, McAdoo MA, Keyserling CH, et al. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract. 2000;54(5):293-9.
Paster, R. Z., McAdoo, M. A., Keyserling, C. H., Nemeth, M. A., Tack, K. J., & Griffin, T. J. (2000). A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. International Journal of Clinical Practice, 54(5), 293-9.
Paster RZ, et al. A Comparison of a Five-day Regimen of Cefdinir With a Seven-day Regimen of Loracarbef for the Treatment of Acute Exacerbations of Chronic Bronchitis. Int J Clin Pract. 2000;54(5):293-9. PubMed PMID: 10954955.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. AU - Paster,R Z, AU - McAdoo,M A, AU - Keyserling,C H, AU - Nemeth,M A, AU - Tack,K J, AU - Griffin,T J, PY - 2000/8/24/pubmed PY - 2000/9/19/medline PY - 2000/8/24/entrez SP - 293 EP - 9 JF - International journal of clinical practice JO - Int J Clin Pract VL - 54 IS - 5 N2 - To compare the efficacy and safety of five-day cefdinir treatment with seven-day loracarbef treatment in patients with acute exacerbations of chronic bronchitis, 586 patients were enrolled in a multicentre, randomised, double-blind trial. Patients received either five days of treatment with cefdinir (n = 291) at 300 mg twice daily or seven days of treatment with loracarbef (n = 295) at 400 mg twice daily. Microbiological assessments were done on sputum specimens obtained at admission and at the two post-therapy visits, if available. The clinical cure rates were 86% (138/160) and 85% (141/166) for the evaluable patients treated with cefdinir and loracarbef, respectively. Respiratory tract pathogens were isolated from 457 (78%) of 586 admission sputum specimens, with the predominant pathogens being Haemophilus parainfluenzae, H. influenzae, Moraxella catarrhalis and Staphylococcus aureus. The microbiological eradication rates at the test-of-cure visit were 88% (193/219 pathogens) and 90% (227/251 pathogens) for the evaluable patients treated with cefdinir and loracarbef, respectively. Adverse event rates while on treatment were 30% and 21% for cefdinir- and loracarbef-treated patients, respectively. These results indicate that a five-day regimen of cefdinir is effective and safe for the treatment of patients with acute exacerbations of chronic bronchitis. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/10954955/A_comparison_of_a_five_day_regimen_of_cefdinir_with_a_seven_day_regimen_of_loracarbef_for_the_treatment_of_acute_exacerbations_of_chronic_bronchitis_ L2 - https://medlineplus.gov/acutebronchitis.html DB - PRIME DP - Unbound Medicine ER -